Skip to content
Use caution Drug recall · FDA · Published April 3, 2013

Boehringer Ingelheim Recalls Oxcarbazepine Oral Suspension Due to Resuspension Issues

Boehringer Ingelheim recalls one lot of Oxcarbazepine Oral Suspension because it did not meet resuspendability requirements. Check your bottle's lot number.

🇺🇸 FDA recall #D-002-2014DrugBoehringer Ingelheim Roxane ›
Take action

Contact the company

Recalling firmBoehringer Ingelheim Roxane Inc1809 Wilson Rd · Columbus, OH 43228-9579
✎ GovInfoNow plain-language explainer

Boehringer Ingelheim Roxane Inc is recalling a specific lot of Oxcarbazepine Oral Suspension, 300 mg/5 mL, in 250 mL bottles. The recall was issued because the product did not meet resuspendability requirements, meaning the medication may not mix properly. This could affect the dosage accuracy for patients taking this prescription drug. Read more at govinfonow.com/recall/48152-boehringer-ingelheim-roxane-inc-recalls-oxcarbazepine-oral-suspension-300-mg.

Source Summary by GovInfoNow · govinfonow.com/recall/48152-boehringer-ingelheim-roxane-inc-recalls-oxcarbazepine-oral-suspension-300-mg · Updated October 13, 2026 · FDA enforcement record: FDA #D-002-2014

Cite this page

“Boehringer Ingelheim Recalls Oxcarbazepine Oral Suspension Due to Resuspension Issues.” GovInfoNow, updated October 13, 2026. https://govinfonow.com/recall/48152-boehringer-ingelheim-roxane-inc-recalls-oxcarbazepine-oral-suspension-300-mg. Based on FDA recall #D-002-2014 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-002-2014%22&limit=1).

The FDA announced on April 3, 2013, that Boehringer Ingelheim Roxane Inc voluntarily recalled Oxcarbazepine Oral Suspension due to resuspension problems. The Class II recall affects 10,267 bottles distributed nationwide.

How to tell if you have it

  • Brand: Boehringer Ingelheim Roxane
  • Product: Oxcarbazepine Oral Suspension, 300 mg/5 mL, 250 mL bottle
  • NDC: 0054-0199-59
  • Lot #: 161304B
  • Expiration: OCT 2013

The hazard

The recalled lot did not meet resuspension requirements, according to the FDA. The agency classified this as a Class II recall.

Context

GovInfoNow's records show Boehringer Ingelheim Roxane Inc has had 12 other recalls since November 5, 2012. Other recent recalls of similar products include FUROSEMIDE Tablets USP (September 25, 2015), Combivent Respimat (July 24, 2015), and Acarbose 50mg Tablets (April 2, 2015).

How to tell if you have this one

Check your bottle for NDC 0054-0199-59 and Lot # 161304B. The expiration date on the bottle is OCT 2013. The product is a prescription-only oral suspension in a 250 mL bottle.

  • Brand
    Boehringer Ingelheim Roxane
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Your Bottle

    Verify if your Oxcarbazepine Oral Suspension bottle has NDC 0054-0199-59 and Lot # 161304B.

  2. Contact Your Pharmacist

    If you have the recalled lot, contact your pharmacist or healthcare provider for instructions on replacement or disposal.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 10 months after the firm started it.

1. Firm started the recall: Apr 3, 201312. FDA classified it Class II: Nov 20, 201323. Published in FDA’s Enforcement Report: Nov 27, 201334. FDA terminated the recall: Feb 11, 2014420132014
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-002-2014 (April 3, 2013) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-002-2014 to see it in context.
  • Plain-language summary written by qwen3.6:35b-a3b on October 13, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA